<?xml version="1.0" encoding="UTF-8"?>
<document id="DrugDDI.d95" origId="Fexofenadine"><sentence id="DrugDDI.d95.s0" origId="s0" text="Drug Interaction with Erythromycin and Ketoconazole Fexofenadine has been shown to exhibit minimal (ca. 5%) metabolism."><entity id="DrugDDI.d95.s0.e0" origId="s0.p1" charOffset="22-34" type="drug" text="Erythromycin"/><entity id="DrugDDI.d95.s0.e1" origId="s0.p3" charOffset="39-51" type="drug" text="Ketoconazole"/><pair id="DrugDDI.d95.s0.p0" e1="DrugDDI.d95.s0.e0" e2="DrugDDI.d95.s0.e1" interaction="?"/></sentence><sentence id="DrugDDI.d95.s1" origId="s1" text="However, co? administration of fexofenadine hydrochloride with either ketoconazole or erythromycin led to increased plasma concentrations of fexofenadine."><entity id="DrugDDI.d95.s1.e0" origId="s1.p16" charOffset="31-57" type="drug" text="fexofenadine hydrochloride"/><entity id="DrugDDI.d95.s1.e1" origId="s1.p17" charOffset="70-82" type="drug" text="ketoconazole"/><entity id="DrugDDI.d95.s1.e2" origId="s1.p19" charOffset="86-98" type="drug" text="erythromycin"/><entity id="DrugDDI.d95.s1.e3" origId="s1.p22" charOffset="141-153" type="drug" text="fexofenadine"/><pair id="DrugDDI.d95.s1.p0" e1="DrugDDI.d95.s1.e0" e2="DrugDDI.d95.s1.e1" interaction="?"/><pair id="DrugDDI.d95.s1.p1" e1="DrugDDI.d95.s1.e0" e2="DrugDDI.d95.s1.e2" interaction="?"/><pair id="DrugDDI.d95.s1.p2" e1="DrugDDI.d95.s1.e0" e2="DrugDDI.d95.s1.e3" interaction="?"/><pair id="DrugDDI.d95.s1.p3" e1="DrugDDI.d95.s1.e1" e2="DrugDDI.d95.s1.e2" interaction="?"/><pair id="DrugDDI.d95.s1.p4" e1="DrugDDI.d95.s1.e1" e2="DrugDDI.d95.s1.e3" interaction="?"/><pair id="DrugDDI.d95.s1.p5" e1="DrugDDI.d95.s1.e2" e2="DrugDDI.d95.s1.e3" interaction="?"/></sentence><sentence id="DrugDDI.d95.s2" origId="s2" text="Fexofenadine had no effect on the pharmacokinetics of either erythromycin or ketoconazole."><entity id="DrugDDI.d95.s2.e0" origId="s2.p23" charOffset="0-12" type="drug" text="Fexofenadine"/><entity id="DrugDDI.d95.s2.e1" origId="s2.p29" charOffset="61-73" type="drug" text="erythromycin"/><entity id="DrugDDI.d95.s2.e2" origId="s2.p31" charOffset="77-89" type="drug" text="ketoconazole"/><pair id="DrugDDI.d95.s2.p0" e1="DrugDDI.d95.s2.e0" e2="DrugDDI.d95.s2.e1" interaction="?"/><pair id="DrugDDI.d95.s2.p1" e1="DrugDDI.d95.s2.e0" e2="DrugDDI.d95.s2.e2" interaction="?"/><pair id="DrugDDI.d95.s2.p2" e1="DrugDDI.d95.s2.e1" e2="DrugDDI.d95.s2.e2" interaction="?"/></sentence><sentence id="DrugDDI.d95.s3" origId="s3" text="In 2 separate studies, fexofenadine hydrochloride 120 mg twice daily (240 mg total daily dose) was co-administered with either erythromycin 500 mg every 8 hours or ketoconazole 400 mg once daily under steady-state conditions to healthy volunteers (n=24, each study)."><entity id="DrugDDI.d95.s3.e0" origId="s3.p33" charOffset="23-54" type="drug" text="fexofenadine hydrochloride 120"/><entity id="DrugDDI.d95.s3.e1" origId="s3.p41" charOffset="127-146" type="drug" text="erythromycin 500 mg"/><entity id="DrugDDI.d95.s3.e2" origId="s3.p43" charOffset="164-183" type="drug" text="ketoconazole 400 mg"/><pair id="DrugDDI.d95.s3.p0" e1="DrugDDI.d95.s3.e0" e2="DrugDDI.d95.s3.e1" interaction="?"/><pair id="DrugDDI.d95.s3.p1" e1="DrugDDI.d95.s3.e0" e2="DrugDDI.d95.s3.e2" interaction="?"/><pair id="DrugDDI.d95.s3.p2" e1="DrugDDI.d95.s3.e1" e2="DrugDDI.d95.s3.e2" interaction="?"/></sentence><sentence id="DrugDDI.d95.s4" origId="s4" text="No differences in adverse events or QTc interval were observed when subjects were administered fexofenadine hydrochloride alone or in combination with either erythromycin or ketoconazole."><entity id="DrugDDI.d95.s4.e0" origId="s4.p61" charOffset="95-121" type="drug" text="fexofenadine hydrochloride"/><entity id="DrugDDI.d95.s4.e1" origId="s4.p66" charOffset="158-170" type="drug" text="erythromycin"/><entity id="DrugDDI.d95.s4.e2" origId="s4.p68" charOffset="174-186" type="drug" text="ketoconazole"/><pair id="DrugDDI.d95.s4.p0" e1="DrugDDI.d95.s4.e0" e2="DrugDDI.d95.s4.e1" interaction="?"/><pair id="DrugDDI.d95.s4.p1" e1="DrugDDI.d95.s4.e0" e2="DrugDDI.d95.s4.e2" interaction="?"/><pair id="DrugDDI.d95.s4.p2" e1="DrugDDI.d95.s4.e1" e2="DrugDDI.d95.s4.e2" interaction="?"/></sentence><sentence id="DrugDDI.d95.s5" origId="s5" text="The findings of these studies are summarized in the following table: Effects on steady-state fexofenadine pharmacokinetics after 7 days of co-administration with fexofenadine hydrochloride 120 mg every 12 hours (two times the recommended twice daily dose) in healthy volunteers (n=24)"><entity id="DrugDDI.d95.s5.e0" origId="s5.p76" charOffset="93-105" type="drug" text="fexofenadine"/><entity id="DrugDDI.d95.s5.e1" origId="s5.p79" charOffset="162-193" type="drug" text="fexofenadine hydrochloride 120"/><pair id="DrugDDI.d95.s5.p0" e1="DrugDDI.d95.s5.e0" e2="DrugDDI.d95.s5.e1" interaction="?"/></sentence><sentence id="DrugDDI.d95.s6" origId="s6" text="Concomitant Drug"><entity id="DrugDDI.d95.s6.e0" origId="s6.p88" charOffset="12-16" type="drug" text="Drug"/></sentence><sentence id="DrugDDI.d95.s7" origId="s7" text="cmaxSS (Peak plasma concentration)"/><sentence id="DrugDDI.d95.s8" origId="s8" text="AUCss(0-12h) (Extent of systemic exposure)"/><sentence id="DrugDDI.d95.s9" origId="s9" text="Erythromycin (500 mg every 8 hrs)"><entity id="DrugDDI.d95.s9.e0" origId="s9.p99" charOffset="0-12" type="drug" text="Erythromycin"/></sentence><sentence id="DrugDDI.d95.s10" origId="s10" text="+82%"/><sentence id="DrugDDI.d95.s11" origId="s11" text="+109%"/><sentence id="DrugDDI.d95.s12" origId="s12" text="Ketoconazole (400 mg once daily)"><entity id="DrugDDI.d95.s12.e0" origId="s12.p105" charOffset="0-12" type="drug" text="Ketoconazole"/></sentence><sentence id="DrugDDI.d95.s13" origId="s13" text="+135%"/><sentence id="DrugDDI.d95.s14" origId="s14" text="+164%"/><sentence id="DrugDDI.d95.s15" origId="s15" text="The changes in plasma levels were within the range of plasma levels achieved in adequate and well-controlled clinical trials."/><sentence id="DrugDDI.d95.s16" origId="s16" text="The mechanism of these interactions has been evaluated in in vitro, in situ, and in vivo animal models."/><sentence id="DrugDDI.d95.s17" origId="s17" text="These studies indicate that ketoconazole or erythromycin co-administration enhances fexofenadine gastrointestinal absorption."><entity id="DrugDDI.d95.s17.e0" origId="s17.p131" charOffset="28-40" type="drug" text="ketoconazole"/><entity id="DrugDDI.d95.s17.e1" origId="s17.p133" charOffset="44-56" type="drug" text="erythromycin"/><entity id="DrugDDI.d95.s17.e2" origId="s17.p135" charOffset="84-96" type="drug" text="fexofenadine"/><pair id="DrugDDI.d95.s17.p0" e1="DrugDDI.d95.s17.e0" e2="DrugDDI.d95.s17.e1" interaction="?"/><pair id="DrugDDI.d95.s17.p1" e1="DrugDDI.d95.s17.e0" e2="DrugDDI.d95.s17.e2" interaction="?"/><pair id="DrugDDI.d95.s17.p2" e1="DrugDDI.d95.s17.e1" e2="DrugDDI.d95.s17.e2" interaction="?"/></sentence><sentence id="DrugDDI.d95.s18" origId="s18" text="This observed increase in the bioavailability of fexofenadine may be due to transport-related effects, such as p-glycoprotein. in vivo animal studies also suggest that in addition to enhancing absorption, ketoconazole decreases fexofenadine gastrointestinal secretion, while erythromycin may also decrease biliary excretion."><entity id="DrugDDI.d95.s18.e0" origId="s18.p138" charOffset="49-61" type="drug" text="fexofenadine"/><entity id="DrugDDI.d95.s18.e1" origId="s18.p142" charOffset="113-125" type="drug" text="glycoprotein"/><entity id="DrugDDI.d95.s18.e2" origId="s18.p150" charOffset="205-217" type="drug" text="ketoconazole"/><entity id="DrugDDI.d95.s18.e3" origId="s18.p152" charOffset="228-240" type="drug" text="fexofenadine"/><entity id="DrugDDI.d95.s18.e4" origId="s18.p154" charOffset="275-287" type="drug" text="erythromycin"/><pair id="DrugDDI.d95.s18.p0" e1="DrugDDI.d95.s18.e0" e2="DrugDDI.d95.s18.e1" interaction="?"/><pair id="DrugDDI.d95.s18.p1" e1="DrugDDI.d95.s18.e0" e2="DrugDDI.d95.s18.e2" interaction="?"/><pair id="DrugDDI.d95.s18.p2" e1="DrugDDI.d95.s18.e0" e2="DrugDDI.d95.s18.e3" interaction="?"/><pair id="DrugDDI.d95.s18.p3" e1="DrugDDI.d95.s18.e0" e2="DrugDDI.d95.s18.e4" interaction="?"/><pair id="DrugDDI.d95.s18.p4" e1="DrugDDI.d95.s18.e1" e2="DrugDDI.d95.s18.e2" interaction="?"/><pair id="DrugDDI.d95.s18.p5" e1="DrugDDI.d95.s18.e1" e2="DrugDDI.d95.s18.e3" interaction="?"/><pair id="DrugDDI.d95.s18.p6" e1="DrugDDI.d95.s18.e1" e2="DrugDDI.d95.s18.e4" interaction="?"/><pair id="DrugDDI.d95.s18.p7" e1="DrugDDI.d95.s18.e2" e2="DrugDDI.d95.s18.e3" interaction="?"/><pair id="DrugDDI.d95.s18.p8" e1="DrugDDI.d95.s18.e2" e2="DrugDDI.d95.s18.e4" interaction="?"/><pair id="DrugDDI.d95.s18.p9" e1="DrugDDI.d95.s18.e3" e2="DrugDDI.d95.s18.e4" interaction="?"/></sentence><sentence id="DrugDDI.d95.s19" origId="s19" text="Drug Interactions with Antacids Administration of 120 mg of fexofenadine hydrochloride (2 x 60 mg capsule) within 15 minutes of an aluminum and magnesium containing antacid (Maalox?) decreased fexofenadine AUC by 41% and cmax by 43%."><entity id="DrugDDI.d95.s19.e0" origId="s19.p160" charOffset="23-31" type="drug" text="Antacids"/><entity id="DrugDDI.d95.s19.e1" origId="s19.p162" charOffset="60-86" type="drug" text="fexofenadine hydrochloride"/><entity id="DrugDDI.d95.s19.e2" origId="s19.p169" charOffset="144-173" type="drug" text="magnesium containing antacid"/><entity id="DrugDDI.d95.s19.e3" origId="s19.p174" charOffset="193-205" type="drug" text="fexofenadine"/><pair id="DrugDDI.d95.s19.p0" e1="DrugDDI.d95.s19.e0" e2="DrugDDI.d95.s19.e1" interaction="?"/><pair id="DrugDDI.d95.s19.p1" e1="DrugDDI.d95.s19.e0" e2="DrugDDI.d95.s19.e2" interaction="?"/><pair id="DrugDDI.d95.s19.p2" e1="DrugDDI.d95.s19.e0" e2="DrugDDI.d95.s19.e3" interaction="?"/><pair id="DrugDDI.d95.s19.p3" e1="DrugDDI.d95.s19.e1" e2="DrugDDI.d95.s19.e2" interaction="?"/><pair id="DrugDDI.d95.s19.p4" e1="DrugDDI.d95.s19.e1" e2="DrugDDI.d95.s19.e3" interaction="?"/><pair id="DrugDDI.d95.s19.p5" e1="DrugDDI.d95.s19.e2" e2="DrugDDI.d95.s19.e3" interaction="?"/></sentence><sentence id="DrugDDI.d95.s20" origId="s20" text="ALLEGRA should not be taken closely in time with aluminum and magnesium containing antacids."><entity id="DrugDDI.d95.s20.e0" origId="s20.p179" charOffset="0-7" type="drug" text="ALLEGRA"/><entity id="DrugDDI.d95.s20.e1" origId="s20.p188" charOffset="62-91" type="drug" text="magnesium containing antacids"/><pair id="DrugDDI.d95.s20.p0" e1="DrugDDI.d95.s20.e0" e2="DrugDDI.d95.s20.e1" interaction="?"/></sentence><sentence id="DrugDDI.d95.s21" origId="s21" text="Interactions with Fruit Juices Fruit juices such as grapefruit, orange and apple may reduce the bioavailability and exposure of fexofenadine."><entity id="DrugDDI.d95.s21.e0" origId="s21.p191" charOffset="52-62" type="drug" text="grapefruit"/><entity id="DrugDDI.d95.s21.e1" origId="s21.p200" charOffset="128-140" type="drug" text="fexofenadine"/><pair id="DrugDDI.d95.s21.p0" e1="DrugDDI.d95.s21.e0" e2="DrugDDI.d95.s21.e1" interaction="?"/></sentence><sentence id="DrugDDI.d95.s22" origId="s22" text="This is based on the results from 3 clinical studies using histamine induced skin wheals and flares coupled with population pharmacokinetic analysis."/><sentence id="DrugDDI.d95.s23" origId="s23" text="The size of wheal and flare were significantly larger when fexofenadine hydrochloride was administered with either grapefruit or orange juices compared to water."><entity id="DrugDDI.d95.s23.e0" origId="s23.p221" charOffset="59-85" type="drug" text="fexofenadine hydrochloride"/><entity id="DrugDDI.d95.s23.e1" origId="s23.p226" charOffset="115-125" type="drug" text="grapefruit"/><entity id="DrugDDI.d95.s23.e2" origId="s23.p230" charOffset="155-160" type="drug" text="water"/><pair id="DrugDDI.d95.s23.p0" e1="DrugDDI.d95.s23.e0" e2="DrugDDI.d95.s23.e1" interaction="?"/><pair id="DrugDDI.d95.s23.p1" e1="DrugDDI.d95.s23.e0" e2="DrugDDI.d95.s23.e2" interaction="?"/><pair id="DrugDDI.d95.s23.p2" e1="DrugDDI.d95.s23.e1" e2="DrugDDI.d95.s23.e2" interaction="?"/></sentence><sentence id="DrugDDI.d95.s24" origId="s24" text="Based on the literature reports, the same effects may be extrapolated to other fruit juices such as apple juice."/><sentence id="DrugDDI.d95.s25" origId="s25" text="The clinical significance of these observations is unknown."/><sentence id="DrugDDI.d95.s26" origId="s26" text="In addition, based on the population pharmacokinetics analysis of the combined data from grapefruit and orange juices studies with the data from a bioequivalence study, the bioavailability of fexofenadine was reduced by 36%."><entity id="DrugDDI.d95.s26.e0" origId="s26.p247" charOffset="89-99" type="drug" text="grapefruit"/><entity id="DrugDDI.d95.s26.e1" origId="s26.p254" charOffset="192-204" type="drug" text="fexofenadine"/><pair id="DrugDDI.d95.s26.p0" e1="DrugDDI.d95.s26.e0" e2="DrugDDI.d95.s26.e1" interaction="?"/></sentence><sentence id="DrugDDI.d95.s27" origId="s27" text="Therefore, to maximize the effects of fexofenadine, it is recommended that ALLEGRA should be taken with water"><entity id="DrugDDI.d95.s27.e0" origId="s27.p262" charOffset="38-50" type="drug" text="fexofenadine"/><entity id="DrugDDI.d95.s27.e1" origId="s27.p266" charOffset="75-82" type="drug" text="ALLEGRA"/><entity id="DrugDDI.d95.s27.e2" origId="s27.p270" charOffset="104-109" type="drug" text="water"/><pair id="DrugDDI.d95.s27.p0" e1="DrugDDI.d95.s27.e0" e2="DrugDDI.d95.s27.e1" interaction="?"/><pair id="DrugDDI.d95.s27.p1" e1="DrugDDI.d95.s27.e0" e2="DrugDDI.d95.s27.e2" interaction="?"/><pair id="DrugDDI.d95.s27.p2" e1="DrugDDI.d95.s27.e1" e2="DrugDDI.d95.s27.e2" interaction="?"/></sentence><sentence id="DrugDDI.d95.s28" origId="s28" text="."/><sentence id="DrugDDI.d95.s29" origId="s29" text="?"/></document>